App-Quantinova.ai

FERTILITY SERVICES IN GERMANY AND THE IMPACT OF COVID-19

Elena Brachimi - American Society for Reproductive Medicine (ASRM) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Can We Monitor Patients On General Wards ? A Single Centre Experience

Sadia Khan - American Society of Anesthesiologists (ASA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Low CD8 T cells predicts benefit from hypoxia-modifying therapy in bladder cancer

Vicky Smith - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Nicotinamide

Combination of reovirus (pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide for patients with glioblastoma multiforme (GBM: Long term follow up results of the ReoGlio phase Ib trial

Susan C. Short - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

GDX012U-001 A phase 1, open-label, dose escalation, and dose expansion study to assess the safety, tolerability, and preliminary antileukemic activity of GDX012 in patients with MRD positive AML

Lisa J. Knowles - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cyclophosphamide

Phase 1/2 results of ceralasertib (Cerala as monotherapy or in combination with acalabrutinib (Acala in high-risk relapsed/refractory (R/R chronic lymphocytic leukemia (CLL

Wojciech Jurczak - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

ACP-196

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Lynsey Drewett - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Olaparib

Precise segmentation of growth patterns in TRACERx lung adenocarcinoma

Xiaoxi Pan - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Automated grading of growth patterns in lung adenocarcinoma-from TRACERx to LATTICe-A

Xiaoxi Pan - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Evaluation of the CNS penetration of a next generation PARP inhibitor, AZD9574, in cynomolgus monkey using positron emission tomography

Andy Pike - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

N/A

Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers

Dominic G. Rothwell - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

Real-world prevalence of MSI/MMR testing for patients with recurrent or advanced endometrial cancer in Europe

Jingchuan Zhang - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

N/A

In vivo efficacy and toxicity of a reduced potency DNA guanine mono-alkylating ADC payload suitable for the treatment of solid tumors

Paul J. M. Jackson - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Solid malignancies

N/A

Apelinergic signalling in hepatocellular carcinoma (HCC: A new therapeutic treatment option

Jamie Beaumont - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Liver cancer

N/A

Expression of cathepsin D in early-stage breast cancer and its prognostic and predictive value

Inas M. Alhudiri - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Identification of ATR inhibitors as therapeutic opportunities in Desmoplastic small round cell tumors

Asuka KAWAI-KAWACHI - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Desmoplastic small round cell tumors

N/A

MDX-124, a novel annexin-A1 antibody, induces significant anti-cancer activity in multiple preclinical models

Fiona C. Dempsey - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Prostate cancer

N/A

Targeting nonsense-mediated decay restores p53 function in HPV-associated head and neck cancers

Jayanthi Gudikote - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

Identification of convergent gene repression mechanisms through integrative genomic and DNA methylation analysis in TRACERx

Francisco Gimeno-Valiente - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Mesotheliomas harbor early clonal fusions involving both tumor suppressor drivers and novel oncogenic alterations

Maymun Jama - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mesothelioma

N/A

Filters

45280 Abstracts